Miss Michelle Tsosie, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: #4 Cone Hill Housing Rd., Rough Rock, AZ 86503 Phone: 928-266-3534 |
News Archive
Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced the closing of its previously announced sale of $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to a single institutional investor. The investor has elected to convert all of its shares of Series 2 Preferred Stock and to receive the 18,853,103 shares of the Company's common stock issuable upon such conversion at the closing.
Isis Pharmaceuticals, Inc. announced today that it has initiated a study for ISIS-DMPK Rx in patients with Myotonic Dystrophy Type 1 (DM1). DM1 is a rare genetic neuromuscular disease caused by the production of toxic dystrophia myotonica-protein kinase (DMPK) RNA in cells. ISIS-DMPKRx is specifically designed to reduce toxic DMPK RNA.
Researchers led by Tanya Stoyanova and Dr. Owen Witte of UCLA's Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have determined how a protein known as Trop2 drives the growth of tumor cells in prostate and other epithelial cancers.
Ben-Gurion University of the Negev Researchers (BGU) have found for the first time that cigarette smoke toxicity impacts the protective biofilm in the lungs, particularly concerning when paired with COVID-19 respiratory issues.
CDC on Friday announced that it will no longer fund an advanced HIV/AIDS monitoring system in eight states and Puerto Rico, the New York Times reports.
› Verified 3 days ago